We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pharmacokinetics and Safety of Moxifloxacin (MFX468)

This study has been terminated.
(slow enrolment of patients and new insights)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01329250
First Posted: April 5, 2011
Last Update Posted: November 18, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
JWC Alffenaar, University Medical Center Groningen
  Purpose
The main objective of this prospective clinical trial is to compare pharmacokinetics and safety and tolerability of a standard dose (400 mg) with an escalated dose (600 mg; 800 mg) of moxifloxacin (MFX). This clinical trial will provide important safety information on MFX in a higher dosage in TB patients.

Condition Intervention Phase
Tuberculosis Drug: Moxifloxacin Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pharmacokinetics and Safety of Moxifloxacin; a Dose Escalation in Patients With Tuberculosis

Resource links provided by NLM:


Further study details as provided by JWC Alffenaar, University Medical Center Groningen:

Primary Outcome Measures:
  • Bound area under the plasma concentration-time curve (AUC0-24h) relative to the minimal inhibitory concentration (MIC) [ Time Frame: 7 days post dosage ]
    % of patients who will reach an AUC0-24h/MIC ratio of at least 100 after administration of 400 mg (i.e. 7 days post dosage) moxifloxacin

  • Unbound AUC0-24h/MIC ratio as predictive parameter for efficacy of unbound MFX dose escalated treatment of tuberculosis [ Time Frame: 7 days post dosage ]
    % of patients who will reach an unbound AUC0-24h/MIC ratio of at least 60 after administration of 400 mg (i.e. 7 day post dosage) moxifloxacin.

  • Bound AUC0-24h/Mutant Prevention Concentration (MPC) ratio [ Time Frame: 7 days post dosage ]
    % of patients who will reach an adequate AUC0-24h/MPC ratio of at least 93 after administration of 400 mg (i.e. 7 days post dosage) moxifloxacin

  • Unbound AUC0-24h/MPC ratio as predictive parameter for efficacy of unbound MFX dose escalated treatment of tuberculosis and suppression of MFX resistance [ Time Frame: 7 days post dosage ]
    % of patients who will reach an unbound AUC0-24h/MPC ratio of at least 53 after administration of 400 mg (i.e. 7 days post dosage) moxifloxacin

  • % of patients having adverse effects, including QT interval prolongation, hypersensitive reactions, diarrhoea, vomiting and hepatic or renal injury [ Time Frame: up to 21 days ]
    • QT interval in msec
    • Percentage of patients developing hepatic toxicity grade ≥ 2 or 3 Common Toxicity Criteria (CTC)
    • Percentage of patients developing renal toxicity grade ≥ 2 CTC

  • Bound area under the plasma concentration-time curve (AUC0-24h) relative to the minimal inhibitory concentration (MIC) [ Time Frame: 14 days post dosage ]
    % of patients who will reach an AUC0-24h/MIC ratio of at least 100 after administration of 600 mg (i.e. 14 days post dosage) moxifloxacin

  • Bound area under the plasma concentration-time curve (AUC0-24h) relative to the minimal inhibitory concentration (MIC) [ Time Frame: 21 days post dosage ]
    % of patients who will reach an AUC0-24h/MIC ratio of at least 100 after administration of 800 mg (i.e. 21 days post dosage) moxifloxacin

  • Unbound AUC0-24h/MIC ratio as predictive parameter for efficacy of unbound MFX dose escalated treatment of tuberculosis [ Time Frame: 14 days post dosage ]
    % of patients who will reach an unbound AUC0-24h/MIC ratio of at least 60 after administration of 600 mg (i.e. 14 days post dosage) moxifloxacin.

  • Unbound AUC0-24h/MIC ratio as predictive parameter for efficacy of unbound MFX dose escalated treatment of tuberculosis [ Time Frame: 21 days post dosage ]
    % of patients who will reach an unbound AUC0-24h/MIC ratio of at least 60 after administration of 800 mg (21 days post dosage) moxifloxacin.

  • Bound AUC0-24h/Mutant Prevention Concentration (MPC) ratio [ Time Frame: 14 post dosage ]
    % of patients who will reach an adequate AUC0-24h/MPC ratio of at least 93 after administration of 600 mg (i.e. 14 days post dosage) moxifloxacin

  • Bound AUC0-24h/Mutant Prevention Concentration (MPC) ratio [ Time Frame: 21 post dosage ]
    % of patients who will reach an adequate AUC0-24h/MPC ratio of at least 93 after administration of 800 mg (i.e. 21 days post dosage) moxifloxacin

  • Unbound AUC0-24h/MPC ratio as predictive parameter for efficacy of unbound MFX dose escalated treatment of tuberculosis and suppression of MFX resistance [ Time Frame: 14 days post dosage ]
    % of patients who will reach an unbound AUC0-24h/MPC ratio of at least 53 after administration of 600 mg (i.e. 14 days post dosage) and moxifloxacin

  • Unbound AUC0-24h/MPC ratio as predictive parameter for efficacy of unbound MFX dose escalated treatment of tuberculosis and suppression of MFX resistance [ Time Frame: 21 days post dosage ]
    % of patients who will reach an unbound AUC0-24h/MPC ratio of at least 53 after administration of 800 mg (i.e. 21 days post dosage) moxifloxacin


Secondary Outcome Measures:
  • Evaluation of the predictive performance of the limited sampling strategies based on a pharmacokinetic population model to calculate AUC0-24h. Several limited sampling points will be evaluated. [ Time Frame: 7 days post dosage ]
    Several limited sampling strategies to predict moxifloxacin AUC0-24h, based on limited sampling points, will be evaluated after administration of 400 mg (i.e. 7 days post dosage)moxifloxacin

  • Correlation between MFX concentration (mg/L) and QT interval (msec) [ Time Frame: 7 days post dosage ]
    Correlation between MFX concentration (mg/L) and QT interval (msec) after administration of 400 mg (i.e. 7 days post dosage) moxifloxacin

  • Correlation of drug exposure (AUC) and adverse effects [ Time Frame: up to 21 days ]
    • vomiting and diarrhoea
    • QT interval (msec)

  • Correlation between the genetic risk score and MFX induced QT prolongation [ Time Frame: up to 21 days ]
  • Evaluation of the predictive performance of the limited sampling strategies based on a pharmacokinetic population model to calculate AUC0-24h. Several limited sampling points will be evaluated. [ Time Frame: 14 days post dosage ]
    Several limited sampling strategies to predict moxifloxacin AUC0-24h, based on limited sampling points, will be evaluated after administration of 600 mg (i.e. 14 days post dosage) moxifloxacin

  • Evaluation of the predictive performance of the limited sampling strategies based on a pharmacokinetic population model to calculate AUC0-24h. Several limited sampling points will be evaluated. [ Time Frame: 21 days post dosage ]
    Several limited sampling strategies to predict moxifloxacin AUC0-24h, based on limited sampling points, will be evaluated after administration of 800 mg (i.e. 21 days post dosage) moxifloxacin

  • Correlation between MFX concentration (mg/L) and QT interval (msec) [ Time Frame: 14 days post dosage ]
    Correlation between MFX concentration (mg/L) and QT interval (msec) after administration of 600 mg (i.e. 14 days post dosage) moxifloxacin

  • Correlation between MFX concentration (mg/L) and QT interval (msec) [ Time Frame: 21 days post dosage ]
    Correlation between MFX concentration (mg/L) and QT interval (msec) after administration of 800 mg (i.e. 21 days post dosage) moxifloxacin


Enrollment: 9
Study Start Date: May 2011
Study Completion Date: August 2016
Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Moxifloxacin
Moxifloxacinin escalating dose
Drug: Moxifloxacin
Patients will start on a standard dose of MFX 400 mg once daily. After 8 days the dose will be increased to 600 mg once daily and on the 15th day of treatment, the dose of MFX will be escalated to 800 mg. In patients who have been treated with rifampicin (RIF) in the past three weeks prior to start of MFX treatment an additional washout period of 3 weeks to reduce the rifampicin induced enzymatic activity will precede the dose escalation.
Other Name: MFX

Detailed Description:

Moxifloxacin (MFX) is a fluoroquinolone with a high in vitro and in vivo bactericidal activity against Mycobacterium tuberculosis. A daily dose of 600-800 mg MFX should be considered for optimal killing of the involved mycobacteria and suppression of drug resistance, which is higher than the currently used dose of 400 mg once daily. In general, safety data to support switching to the suggested higher dose are limited.

For this purpose, twenty tuberculosis patients will start on a standard dose of MFX 400 mg once daily. After 8 days the dose will be increased to 600 mg once daily and on the 15th day of treatment, the dose of MFX will be escalated to 800 mg. In patients who have been treated with rifampicin (RIF) in the past three weeks prior to start of MFX treatment an additional washout period of 3 weeks to reduce the rifampicin induced enzymatic activity will precede the dose escalation.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with TB, with Mycobacterium tuberculosis (or M. africanum) by culture
  • Starting treatment with MFX in a dose of 400 mg as part of their TB treatment

Exclusion Criteria:

  • Contra-indication for MFX
  • Baseline QTc-interval > 450 msec
  • History of resuscitation
  • History of ventricular tachycardia (including Torsades de Pointes)
  • Family history of sudden cardiac death or Torsades de Pointes
  • Additional risk factors for Torsades de Pointes (including known heart failure, Left ventricular hypertrophy)
  • Use of concomitant treatment with QT/QTc prolonging drugs (including anti-dysrhythmics class IA and III, antipsychotics, tricyclic antidepressants or the antihistaminic drug terfenadine)
  • Abnormal electrolytes (K, Mg, Na, Ca)
  • Abnormal cardiac repolarisation on screening/baseline ECG
  • History of adverse events to fluoroquinolones
  • HIV co-infection
  • RIF treatment during last 3 weeks before start of the study. After a washout period of 3 weeks the patient can be included.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01329250


Locations
Netherlands
University Medical Center Groningen
Groningen, Netherlands
Sponsors and Collaborators
University Medical Center Groningen
Investigators
Study Chair: Jos GW Kosterink, PharmD, PhD Univeristy Medical Center Groningen
Principal Investigator: Jan-Willem C Alffenaar, PharmD, PhD University Medical Center Groningen
  More Information

Responsible Party: JWC Alffenaar, PharmD, PhD, University Medical Center Groningen
ClinicalTrials.gov Identifier: NCT01329250     History of Changes
Other Study ID Numbers: MFX468
First Submitted: March 8, 2011
First Posted: April 5, 2011
Last Update Posted: November 18, 2016
Last Verified: November 2016

Keywords provided by JWC Alffenaar, University Medical Center Groningen:
Tuberculosis
Moxifloxacin
Pharmacokinetics
Safety

Additional relevant MeSH terms:
Tuberculosis
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Moxifloxacin
Fluoroquinolones
Norgestimate, ethinyl estradiol drug combination
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Contraceptives, Oral, Combined
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Nucleic Acid Synthesis Inhibitors